Where does ZEAL stock trade?

Zealand Pharma A/S (ZEAL) is listed on NASDAQ.

What sector and industry is ZEAL in?

Zealand Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Zealand Pharma A/S go public?

Zealand Pharma A/S (ZEAL) completed its IPO in 2017.

What are analysts saying about ZEAL?

Zealand Pharma A/S has had 4 recent analyst actions on file. The most recent action was from Berenberg: Buy on 2024-03-05.

What companies are similar to ZEAL?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZEAL side-by-side with any of them on Quantisnow.

How can I track ZEAL on Quantisnow?

Quantisnow aggregates Zealand Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZEAL to receive live email and push alerts on every new disclosure.

ZEAL

NASDAQ

Zealand Pharma A/S

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2017

$17.38-3.01 (-14.76%)

Follow Website

News25/Ratings4

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

News · 26 weeks49+60%

2026-03-012026-08-23

Mix2990d

Other25(86%)
Earnings2(7%)
Dividends1(3%)
M&A1(3%)

Latest news

25 items

ZEAL FAQ

7 questions

What does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has...
Where does ZEAL stock trade?
Zealand Pharma A/S (ZEAL) is listed on NASDAQ.
What sector and industry is ZEAL in?
Zealand Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Zealand Pharma A/S go public?
Zealand Pharma A/S (ZEAL) completed its IPO in 2017.
What are analysts saying about ZEAL?
Zealand Pharma A/S has had 4 recent analyst actions on file. The most recent action was from Berenberg: Buy on 2024-03-05.
What companies are similar to ZEAL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZEAL side-by-side with any of them on Quantisnow.
How can I track ZEAL on Quantisnow?
Quantisnow aggregates Zealand Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZEAL to receive live email and push alerts on every new disclosure.